{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:01:26Z","timestamp":1793275286819,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejphar.2020.172957","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T02:24:03Z","timestamp":1580178243000},"page":"172957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset"],"prefix":"10.1016","volume":"873","author":[{"given":"Lamia","family":"Sid-Otmane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adjia","family":"Hamadjida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Panisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.172957_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-244X-13-143","article-title":"A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia","volume":"13","author":"Adams","year":"2013","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.ejphar.2020.172957_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.172957_bib3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2020.172957_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2020.172957_bib5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172957_bib6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.172957_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","article-title":"The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats","volume":"291","author":"Cartmell","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.172957_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.172957_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.172957_bib10","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.172957_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2020.172957_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2020.172957_bib14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease. The French clozapine Parkinson study group","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.172957_bib15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.172957_bib16","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib17","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchromb.2017.07.007","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma","volume":"1061\u20131062","author":"Gaudette","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ejphar.2020.172957_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2018.06.036","article-title":"Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset","volume":"1093\u20131094","author":"Gaudette","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ejphar.2020.172957_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonzalez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.172957_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FBP.0000000000000441","article-title":"Classic animal models of Parkinson's disease: a historical perspective","volume":"30","author":"Hamadjida","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172957_bib22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00210-018-1549-6","article-title":"Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset","volume":"391","author":"Hamadjida","year":"2018","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172957_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pnpbp.2017.09.001","article-title":"The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset","volume":"81","author":"Hamadjida","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.172957_bib25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00702-017-1830-8","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease","volume":"125","author":"Hamadjida","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejphar.2020.172957_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","article-title":"The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset","volume":"234","author":"Hamadjida","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.ejphar.2020.172957_bib27","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0028-3908(97)00170-6","article-title":"LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats","volume":"36","author":"Helton","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3565(24)37253-2","article-title":"Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors","volume":"284","author":"Helton","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.172957_bib29","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172957_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045587","article-title":"The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset","volume":"7","author":"Huot","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.172957_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib32","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.172957_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","article-title":"UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset","volume":"82","author":"Huot","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib34","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1021\/jm034015u","article-title":"Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine","volume":"46","author":"Johnson","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.172957_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.ejphar.2020.172957_bib36","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172957_bib37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/PL00005284","article-title":"LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats","volume":"358","author":"Konieczny","year":"1998","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172957_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00221-018-5434-9","article-title":"5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review","volume":"237","author":"Kwan","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2020.172957_bib39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","article-title":"Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268","volume":"117","author":"Lorrain","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2020.172957_bib40","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.172957_bib41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm9606756","volume":"40","author":"Monn","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.172957_bib42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.170506","article-title":"Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats","volume":"335","author":"Nikiforuk","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.172957_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1469-8749.2001.tb04139.x","article-title":"Pharmacology and neuroprotective actions of mGlu receptor ligands","volume":"43","author":"O'Neill","year":"2001","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejphar.2020.172957_bib44","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172957_bib45","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaneurol.2017.3205","article-title":"ADS-5102 (amantadine) extended release for levodopa-induced dyskinesia","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejphar.2020.172957_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group","volume":"340","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.172957_bib47","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.172957_bib48","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.ejphar.2020.172957_bib49","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/brain\/awf269","article-title":"Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment","volume":"125","author":"Picconi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.172957_bib50","series-title":"Clinical Pharmacokinetics: Concepts and Application","author":"Rowland","year":"1995"},{"key":"10.1016\/j.ejphar.2020.172957_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(96)00160-8","article-title":"LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors","volume":"36","author":"Schoepp","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.172957_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2020.172957_bib53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0091-3057(02)00850-X","article-title":"The anxiolytic action of mGlu2\/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam","volume":"73","author":"Tizzano","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2020.172957_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.172957_bib55","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2020.172957_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2003.08.065","article-title":"Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets","volume":"993","author":"Zhang","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2020.172957_bib57","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920300492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920300492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:08:15Z","timestamp":1762142895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920300492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":57,"alternative-id":["S0014299920300492"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172957","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172957"}}